Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NGL Fine-ChemNSE:NGLFINE +7.55%78 3-Year ROIIC % is 10.05 as of Mar. 2026, which is 6% above its 10-year median of 9.51. GuruFocus rates NSE:NGLFINE with a GF Score™ of 78/100 and a GF Value™ of ₹2,842.12 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 946 Drug Manufacturers companies, NGL Fine-Chem ranks better than 59.83% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
NGL Fine-Chem's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 10.05%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for NGL Fine-Chem's 3-Year ROIIC % or its related term are showing as below:
NSE:NGLFINE's 3-Year ROIIC % is ranked better than 59.83% of 946
companies
in the Drug Manufacturers industry
Industry Median: 3.72
vs NSE:NGLFINE: 10.05
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
NGL Fine-Chem 3-Year ROIIC % Related Terms
NGL Fine-Chem 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for NGL Fine-Chem's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:NGLFINE vs LLY, JNJ, ABBV: 3-Year ROIIC % Comparison
For the Drug Manufacturers - General subindustry, NGL Fine-Chem's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NGL Fine-Chem 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, NGL Fine-Chem's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where NGL Fine-Chem's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
NGL Fine-Chem (NSE:NGLFINE) has a 3-Year ROIIC % of 10.05 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on NGL Fine-Chem and its competitors. This is near median its historical median of 9.51. According to the industry distribution chart, NGL Fine-Chem ranks #380 out of 946 companies in the Drug Manufacturers industry, placing it in the top 40.2%.
Is NGL Fine-Chem's 3-Year ROIIC % too high?
NGL Fine-Chem's current 3-Year ROIIC % of 10.05 is near median its 10-year median of 9.51. The Drug Manufacturers industry median 3-Year ROIIC % is 3.72. NGL Fine-Chem's value of 10.05 is 170.2% above this industry median. Based on the distribution chart, NGL Fine-Chem ranks #380 out of 946 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, NGL Fine-Chem has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NGL Fine-Chem's 3-Year ROIIC % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, NGL Fine-Chem ranks #380 out of 946 companies for 3-Year ROIIC %. This puts NGL Fine-Chem in the upper half of its industry. The industry median 3-Year ROIIC % is 3.72. NGL Fine-Chem's value of 10.05 is 170.2% above this benchmark. While the company's 10-year median is 9.51 vs. the industry median of 3.72, NGL Fine-Chem has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.72, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NGL Fine-Chem's current 3-Year ROIIC % of 10.05 is 170.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on NGL Fine-Chem and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NGL Fine-Chem's current 3-Year ROIIC % is 10.05, which is near median its own 10-year median of 9.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NGL Fine-Chem stock overvalued right now?
Based on GuruFocus' analysis, NGL Fine-Chem (NSE:NGLFINE) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,842.12, compared to a current price of ₹3,237.40 — trading 13.9% above its estimated fair value. The current 3-Year ROIIC % is 10.05, which is near median its 10-year median of 9.51 and 170.2% above the Drug Manufacturers industry median of 3.72. NGL Fine-Chem's overall GF Score™ is 78/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For NGL Fine-Chem (NSE:NGLFINE), the current 3-Year ROIIC % is 10.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NGL Fine-Chem (NSE:NGLFINE) Overvalued in 2026?
Based on GuruFocus' analysis, NGL Fine-Chem stock appears to be overvalued.
The current stock price of ₹3,237.40 is trading 13.9% above its estimated GF Value™ of ₹2,842.12.
GuruFocus considers NGL Fine-Chem to be Modestly Overvalued.
Key valuation signals for NSE:NGLFINE:
3-Year ROIIC %: 10.05 (near median its 10-year median of 9.51)
GF Value™: ₹2,842.12 vs. price of ₹3,237.40 (13.9% above fair value)
Industry Position: 170.2% above the Drug Manufacturers median (#380 of 946)
No single metric tells the full story. See the NSE:NGLFINE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NGL Fine-Chem Ltd is an Indian company engaged in the pharmaceutical business. It is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health, catering to various companies to custom-manufacture pharmaceuticals. The company's product portfolio comprises animal health APIs such as homidium chloride, nitroxynil, clorsulon, decoquinate, fenbendazole, etc.; human health APIs such as nitazoxanide and atovaquone; drug intermediates and specialty chemicals; and finished dosage forms such as diminazene aceturate granules and homidium chloride tablets. Geographically, the group generates maximum revenue from the Asia-Pacific region, and the rest from India, Europe, the USA, and the rest of the world.
78GF Score
Get the complete analysis for NSE:NGLFINE
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NGLFINE has been successfully added to your 
